Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and ...

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

Boltz-2's development was led by the Boltz team at MIT under the supervision of Professors Regina Barzilay and Tommi Jaakkola alongside a team of researchers from MIT and Recursion. For more ...

The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.

While Artificial Intelligence (AI) has emerged as groundbreaking and significantly impacting various sectors and enhancing quality of life, the ...

Key Takeaways Top YouTube channels offer beginner-to-advanced DSA tutorials for all skill levels.Expert-led content helps ace ...

Cardiovascular diseases cause one death every 33 seconds in America. Diagnosing these conditions, which account for ...

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD ... chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill ...